Filing Analysis
CalciMedica, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended September 30, 2025. The filing serves as a formal announcement of the earnings release issued on November 12, 2025.
📋 Key Facts
- The company released financial results for the fiscal quarter ending September 30, 2025.
- The report was filed on November 12, 2025.
- The filing includes a press release as Exhibit 99.1.
CalciMedica, Inc. has filed a prospectus supplement to increase the maximum aggregate offering price of its common stock under an existing at-the-market (ATM) offering agreement with H.C. Wainwright & Co.
🚩 Red Flags
- Increased ATM capacity often indicates a need for immediate liquidity to fund ongoing operations in a micro-cap biotech context.
📋 Key Facts
- Increased maximum aggregate offering price from $4,450,000 to $9,700,000.
- The increase applies to shares issuable under the existing Offering Agreement dated August 11, 2023.
- The offering is being conducted via an at-the-market (ATM) program with H.C. Wainwright & Co.
- Filed on November 6, 2025.
CalciMedica, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended June 30, 2025. The filing serves as a formal announcement of the earnings release via press release.
📋 Key Facts
- Report date: August 12, 2025
- Reporting period: Fiscal quarter ended June 30, 2025
- The company is an emerging growth company.
- Financial results were released via press release (Exhibit 99.1).
CalciMedica, Inc. held its 2025 Annual Meeting of Stockholders on June 24, 2025. The meeting resulted in the election of three Class II directors and the ratification of Baker Tilly US, LLP as the independent auditor.
📋 Key Facts
- Stockholders approved an amendment to the 2023 Equity Incentive Plan to increase authorized shares by 600,000.
- Three directors (Rachel Leheny, Eric W. Roberts, and Frederic Guerard) were elected to three-year terms ending in 2028.
- Baker Tilly US, LLP was ratified as the independent registered public accounting firm for fiscal year 2025.
- As of April 28, 2025, there were 13,971,990 shares outstanding entitled to vote.
CalciMedica, Inc. announced a change in its independent registered public accounting firm following the merger of Moss Adams LLP with Baker Tilly US, LLP. The company has appointed Baker Tilly as its successor auditor effective June 3, 2025.
🚩 Red Flags
- None identified; the change is due to a merger rather than auditor resignation due to disputes.
📋 Key Facts
- Moss Adams LLP merged with Baker Tilly US, LLP on June 3, 2025.
- Baker Tilly US, LLP is the successor independent registered public accounting firm.
- The change was triggered by the merger of the previous auditor, Moss Adams.
- No disagreements regarding accounting principles or auditing procedures were reported with Moss Adams.
- The company's 2024 audit report from Moss Adams did not contain an adverse opinion, disclaimer, or qualification.
CalciMedica, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended March 31, 2025. The filing serves as a formal announcement of the company's quarterly earnings release.
📋 Key Facts
- Reporting period: Fiscal quarter ended March 31, 2025.
- Filing date: May 14, 2025.
- The filing includes Exhibit 99.1, which is the official press release regarding financial results.
CalciMedica, Inc. filed an 8-K to announce its financial results for the fiscal year ended December 31, 2024. The filing serves as a formal notification of the release of annual earnings data.
📋 Key Facts
- Report date: March 27, 2025
- Reporting period: Fiscal year ended December 31, 2024
- The company issued a press release (Exhibit 99.1) containing the financial results.
- Company is an emerging growth company.
CalciMedica entered into a $32.5 million Loan and Security Agreement with Avenue Venture Opportunities Fund II, L.P., receiving an initial $10 million tranche on February 28, 2025. The agreement includes milestone-based funding tranches, high interest rates, and warrants for equity issuance.
🚩 Red Flags
- High interest rate floor of 12.75% suggests significant risk profile.
- Milestone-based funding (Tranches 2 and 3) creates execution risk; failure to meet clinical milestones could result in a liquidity gap.
- Lien on all company assets, including intellectual property, provides lender with significant leverage/control.
- Potential for significant dilution via warrants and conversion rights.
📋 Key Facts
- Total aggregate principal amount of up to $32,500,000 in growth capital loans.
- Tranche 1: $10,000,000 funded on February 28, 2025.
- Tranche 2: Up to $7,500,000 available between Sept 1, 2025 and March 31, 2026, subject to clinical trial milestones.
- Tranche 3: Up to $15,000,000 available between Oct 1, 2025 and March 31, 2026, subject to clinical trial milestones and lender approval.
- Interest rate is the greater of 12.75% or Prime + 5.00%.
- Maturity date set for September 1, 2028.
- The loan is secured by a lien on all company assets, including intellectual property.
- Issuance of a warrant to purchase 641,163 shares at $2.32 per share (exercisable until Feb 28, 2030).
- Lender has conversion rights for up to $2,000,000 of the principal into common stock.
CalciMedica released post-hoc analysis data from its Phase 2 CARDEA trial of Auxora for treating severe COVID-19 pneumonia. The data highlights significant mortality reductions, particularly in a patient subset with Acute Kidney Injury (AKI).
🚩 Red Flags
- Data is from a 'post-hoc' analysis, which is exploratory and not part of the original primary endpoint design, making it subject to higher scrutiny by regulators like the FDA.
📋 Key Facts
- Post-hoc analysis of the Phase 2 CARDEA trial was conducted on patients with severe COVID-19 pneumonia.
- In a subset of 38 patients with Acute Kidney Injury (AKI), Auxora showed a 62.7% relative reduction in mortality at day 30 compared to placebo.
- Mortality rate for the AKI subset: 17.4% (4/23) for Auxora vs. 46.7% (7/15) for placebo.
- In the entire study population (n=261), Auxora showed a 56.3% relative reduction in mortality at day 30 compared to placebo (p = 0.017).
- The absolute reduction in mortality for the AKI subset was 29.3%.
- Biomarker data indicated increases in angiopoietin-1 and decreases in angiopoietin-2 and D-dimers in treated patients.
CalciMedica, Inc. announced the resignation of Eric Bjerkholt from the Board of Directors and his roles as Chair and Audit Committee member, effective January 15, 2025. Simultaneously, the company appointed Dr. Alan Glicklich to the Board with a term expiring in 2027.
🚩 Red Flags
- Departure of the Audit Committee Chair is a sensitive governance event, though no disagreement was cited.
📋 Key Facts
- Eric Bjerkholt resigned from the Board, including his roles as Chair and Audit Committee member, effective January 15, 2025.
- The company stated Bjerkholt's resignation is not due to any disagreement regarding operations, policies, or practices.
- Dr. Alan Glicklich was appointed as a Class I director, effective January 15, 2025.
- Dr. Glicklich will receive an annual cash retainer of $40,000 (pro-rated) and an option to purchase 20,000 shares of common stock vesting over three years.